Vanguard Group Inc. Raises Holdings in Senseonics Holdings, Inc. (NYSE:SENS)

Vanguard Group Inc. raised its position in shares of Senseonics Holdings, Inc. (NYSE:SENS) by 0.7% in the first quarter, Holdings Channel.com reports. The fund owned 22,525,039 shares of the company’s stock after buying an additional 155,715 shares during the quarter. Vanguard Group Inc.’s holdings in Senseonics were worth $11,963,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SENS. State Board of Administration of Florida Retirement System acquired a new position in shares of Senseonics in the 1st quarter valued at about $91,000. Mirae Asset Global Investments Co. Ltd. increased its position in Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares in the last quarter. Finally, RPO LLC purchased a new position in Senseonics in the fourth quarter valued at approximately $37,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Price Performance

Shares of NYSE SENS opened at $0.39 on Wednesday. The stock has a fifty day moving average price of $0.42 and a 200 day moving average price of $0.49. The company has a current ratio of 3.96, a quick ratio of 3.70 and a debt-to-equity ratio of 1.79. Senseonics Holdings, Inc. has a 12-month low of $0.37 and a 12-month high of $0.75.

Senseonics (NYSE:SENS) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative return on equity of 225.98% and a negative net margin of 335.15%. On average, analysts expect that Senseonics Holdings, Inc. will post -0.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Senseonics in a research note on Monday. They set a “sell” rating for the company.

Senseonics Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.